Short answer
Pacira BioSciences, Inc. (PCRX) filed an 8-K current report with the SEC on June 30, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Divestiture of iovera° cryoanalgesia business to Zimmer Biomet for up to $140.0 million.
Pacira BioSciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Divestiture of iovera° cryoanalgesia business to Zimmer Biomet for up to $140.0 million
- $70.0 million upfront payment, subject to customary cash, receivables, debt, expenses and inventory adjustments
- Up to $70.0 million additional consideration tied to annual revenue milestones through December 31, 2031
- 66 employees, approximately 8% of Pacira’s workforce, expected to transfer to Zimmer Biomet
- Closing expected in third quarter 2026, subject to customary conditions; Pacira accepts post-closing restrictive covenants
Item 7.01 · Regulation FD Disclosure
- Pacira announced a Purchase Agreement on June 30, 2026, signaling a potentially material corporate transaction
- Exhibit 99.1 contains the agreement and transaction terms investors need to assess consideration, obligations, and strategic impact
Item EX-99.1 · Exhibit EX-99.1
- Divestiture transfers Pacira’s iovera° rights to Zimmer Biomet, advancing Pacira’s transition toward an innovative biopharmaceutical company
- Pacira receives $70 million upfront and up to $70 million in revenue-based milestones through December 31, 2031
- Upfront net proceeds intended to strengthen the balance sheet and repay Pacira’s senior secured revolving credit facility
- Collaboration preserves potential upside from the spasticity program, including compensation tied to registrational success and regulatory approval
- Closing expected in Q3 2026, subject to customary conditions and a transition services agreement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pacira BioSciences, Inc. 8-K filings
Get the next PCRX 8-K as it lands
Follow PCRX for push alerts, or ask the research agent what this filing means.